Tag: biotechnology
Cue Biopharma Stock Analysis: Buy or Sell? Cash Burn, Dilution & Valuation
Cue Biopharma (CUE) is rated Sell as cash burn and dilution risk outweigh the promise of its Immuno-STAT pipeline. A 5.1x EV/revenue valuation and just $27.1 million of year-end cash leave little room for delay before clinical proof arrives.
Altimmune Stock Analysis: Buy or Sell? Valuation, Cash Burn & Phase 3
Altimmune (ALT) is rated Sell as the stock already prices in Phase 3 success while the business remains pre-revenue. Despite $326.3 million in cash and a strong current ratio, negative free cash flow and heavy development spending keep the risk profile elevated.
GeneDx Stock Analysis: Buy or Sell? Valuation, Cash Flow & Margins
GeneDx Holdings Corp. (WGS) is rated Sell as the market prices in a clean earnings recovery that cash flow and margin trends do not yet support. Revenue growth is improving, but positive free cash flow remains elusive and reimbursement pressure could delay a rerating.